Initial Beneficial Ownership · 3
ADARx Pharmaceuticals, Inc.
ADRXNASDAQEQUITYCurrent
Initial Beneficial Ownership
Structured filing — 3
ownership.xml
Filing details
- Report period
- 2026-09-24
- Issuer
- ADARx Pharmaceuticals, Inc.
- Issuer CIK
- 0001802369
- Trading symbol
- ADRX
Reporting owner 1
- Name
- SR ONE CAPITAL MANAGEMENT, LLC
- Reporting owner CIK
- 0001853723
- Relationship
- 10% owner
- Address
- 929 MAIN STREET, SUITE 200, REDWOOD CITY, CA, 94063
Derivative holdings
| Security | Conversion / exercise price | Exercisable | Expires | Underlying security | Underlying shares | Ownership | Nature of ownership |
|---|---|---|---|---|---|---|---|
| Series B Preferred Stock | [F1] | [F1] | [F1] | Common Stock | 3,334,938 | I | See Note 2[F2] |
| Series B-1 Preferred Stock | [F1] | [F1] | [F1] | Common Stock | 1,113,666 | I | See Note 2[F2] |
| Series C Preferred Stock | [F1] | [F1] | [F1] | Common Stock | 512,897 | I | See Note 2[F2] |
| Series C Preferred Stock | [F1] | [F1] | [F1] | Common Stock | 1,538,691 | I | See Note 3[F3] |
| Series B Preferred Stock | [F1] | [F1] | [F1] | Common Stock | 1,667,468 | I | See Note 4[F4] |
| Series B-1 Preferred Stock | [F1] | [F1] | [F1] | Common Stock | 169,001 | I | See Note 4[F4] |
Table key
- I
- Indirect
Footnotes
- F1
- Each share of Series B Preferred Stock, Series B-1 Preferred Stock and Series C Preferred Stock (collectively, the "Preferred Stock") will automatically convert on a 1-for-1.1717 basis into shares of Common Stock upon the closing of the Issuer's initial public offering without payment of further consideration. Share numbers give effect to such conversion. The Preferred Stock has no expiration date.↩ 1↩ 2↩ 3↩ 4↩ 5↩ 6↩ 7↩ 8↩ 9↩ 10↩ 11↩ 12↩ 13↩ 14↩ 15↩ 16↩ 17↩ 18
- F2
- The securities are directly held by SR One Capital Fund I Aggregator, LP ("SR One Fund I Aggregator"). SR One Capital Partners I, LP ("SR One Partners I") is the sole general partner of SR One Fund I Aggregator, and SR One Capital Management, LLC ("SR One Capital Management") is the sole general partner of SR One Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.↩ 1↩ 2↩ 3
- F3
- The securities are directly held by SR One Capital Opportunities Fund I, LP ("SR One Opportunities Fund I"). SR One Capital Opportunities Partners I, LP ("SR One Opportunities Partners I") is the sole general partner of SR One Opportunities Fund I, and SR One Capital Management is the sole general partner of SR One Opportunities Partners I. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Opportunities Partners I, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.↩ 1
- F4
- The securities are directly held by SR One Co-Invest III, LLC ("SR One Co-Invest"). SR One Co-Invest III Manager LLC ("SR One Co-Invest Manager") is the managing member of SR One-Co-Invest, and SR One Capital Management is the managing member of SR One Co-Invest Manager. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Co-Invest Manager, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.↩ 1↩ 2
Signature 1
- Signed
- /s/ Sasha Keough, attorney-in-fact for SR One Capital Management, LLC
- Date
- 2026-09-24
Filed exhibits
- EX-24.POA ↗adrx-ex24_poa.htm
Company context
We are a late-clinical stage biotechnology company focused on developing next-generation siRNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs. Our team is united by a shared vision to build a leading next-generation siRNA therapeutics company.
Current securities
Recent company filings
- SCHEDULE 13G - filed by Li Zhen regarding ADARx Pharmaceuticals, Inc.Nov 13, 2026
- 10-Q filingNov 12, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureNov 12, 2026
- SCHEDULE 13G - filed by LAV Biosciences Fund V, L.P. regarding ADARx Pharmaceuticals, Inc.Oct 16, 2026
- SCHEDULE 13D - filed by ORBIMED ADVISORS LLC regarding ADARx Pharmaceuticals, Inc.Oct 2, 2026